Theolytics is a biotech company working to develop curative cancer therapies. We are a University of Oxford spin-out, backed by Oxford Sciences Innovation (OSI), harnessing viruses to combat cancer.
A step-change in the oncolytic viral therapy field, our Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population.
Our team is one of the most important elements of who we are and what we do. We combine world leading scientific expertise – encompassing virology, cancer biology, immunology, bioinformatics, and molecular biology – with a track record of translating oncolytic viral therapies into the clinic.
If you think your principles are aligned with ours, we want to hear from you!